Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.73 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.73 |
| ▸ | CYP2A6 | P11509 | 8/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142957 | 1.00 | DYRK1A (0.73) | DYRK1ADYRK1BCYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL29992735 | 1.00 | DYRK1A (0.73) | DYRK1ADYRK1BCYP2A6CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4832941 | 0.98 | DYRK1A (0.71) | DYRK1ADYRK1BCYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL1256370 | 0.87 | DYRK1A (0.58) | DYRK1ADYRK1BCYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL1257460 | 0.82 | PIK3CD (0.73) | DYRK1ADYRK1BALDH1A1CYP1A2MAP4K4 | |
| SCHEMBL29740321 | 0.82 | PIK3CD (0.73) | DYRK1ADYRK1BALDH1A1CYP1A2MAP4K4 | |
| SCHEMBL10918242 | 0.81 | CYP2A6 (0.65) | DYRK1ADYRK1BCYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL29568613 | 0.80 | MAP4K4 (0.64) | DYRK1ADYRK1BCYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL68829 | 0.80 | MAP4K4 (0.64) | DYRK1ADYRK1BCYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL24534338 | 0.79 | CYP2A6 (0.88) | DYRK1ADYRK1BCYP2A6CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| CN-110818683-B | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2023-04-14 | — | — | CN | disclosed |
| US-11434245-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-06 | — | — | US | disclosed |
| US-11434245-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-06 | — | — | US | disclosed |
| EP-3822258-B1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THIN FILM FORMED FROM THE COMPOSITION | SAMSUNG DISPLAY CO LTD (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-3911640-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | disclosed |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-18 | — | — | US | disclosed |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-18 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1737852-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050227989-A1 | Polycyclic thiazoles as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-4448780-A | N-(Lower-alkyl)-N'-[5-(pyridinyl)-2-pyridinyl]ureas and cardiotonic use thereof | STERLING DRUG INC. (US) | 1984-05-15 | — | — | US | disclosed |
| US-4420617-A | 5(Pyridinyl)pyridin-2-amines | STERLING DRUG INC. (US) | 1983-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | KCNJ2, KCNJ1, KCNJ11 | DYRK1A 2978/4885DYRK1B 3156/4885CYP2A6 3440/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | DYRK1A 4875/4885DYRK1B 4864/4885CYP2A6 53/4885 |
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | KCNJ2, KCNH2, KCNQ1 | DYRK1A 2097/4885DYRK1B 2539/4885CYP2A6 3061/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | DYRK1A 4875/4885DYRK1B 4864/4885CYP2A6 53/4885 |
| US-11434245-B2 | WNT pathway modulators | WNT1, WNT3A, WNT3 | DYRK1A 388/4885DYRK1B 407/4885CYP2A6 1650/4885 |
| US-20050227989-A1 | Polycyclic thiazoles as potassium ion channel modulators | KCNJ2, KCNA3, KCNN3 | DYRK1A 2438/4885DYRK1B 2862/4885CYP2A6 3880/4885 |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | KCNJ2, KCNH2, KCNJ1 | DYRK1A 3511/4885DYRK1B 3828/4885CYP2A6 3815/4885 |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | DYRK1A 878/4885DYRK1B 1220/4885CYP2A6 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.